Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms Pro-PEG3-BA |
Action degraders |
Mechanism EGFR L858R degraders(EGFR exon 21 L858R mutation degraders), EGFR T790M degraders(Epidermal Growth Factor Receptor T790M degraders), EML4-ALK degraders(EMAP Like 4-Anaplastic lymphoma kinase fusion degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-Small Cell Lung Cancer | Discovery | China | 12 Aug 2024 |





